News

JFK Airport Chooses LOGIPIX for Airside Virtual Ramp Control System

JFK Millennium Partners, the consortium leading a $4.2 billion redevelopment at JFK International Airport, has selected LOGIPIX US Corporation to implement an advanced Virtual Ramp Control System at the new JFK Terminal 6. This pioneering technology promises to revolutionize airport operations by enhancing security, efficiency, and safety on the ground.

LOGIPIX, a global leader in high-resolution intelligent computer vision solutions, was chosen after a rigorous selection process for its advanced capabilities and track record of successful implementations in high-volume commercial airside environments, such as LaGuardia Airport.

The Virtual Ramp Control System will leverage LOGIPIX’ innovative multi-sensor panoramic video technology and Airside Augmented Reality Solution (LAARS) software to provide monitoring and analysis of ground activities with live object classification and tracking, supporting the Terminal 6 gate operations center. Integrating high-resolution cameras, intelligent AI analytics, and advanced control features, the system will enhance the efficiency of aircraft management with real time decision-making support and improved situational awareness.

“We are thrilled to work with JFK Millennium Partners to deploy our Virtual Ramp Control System,” said Mike Broggie, President of LOGIPIX US Corporation. “This collaboration underscores our commitment to provide cutting-edge solutions that address the evolving needs of modern airports, and we are confident that our technology will contribute to JFK’s innovative transformation into a world-class facility.”

Implementation of the Virtual Ramp Control System will occur in two phases during construction of Terminal 6.

Recent News

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients

08/14/2026

Transforming the finance function in life sciences: Empower scalable growth

Life sciences companies operate in one of the most complex business environments. Long R&D timelines, limited early-stage revenue, and dependence on external funding create a financial landscape where every decision carries strategic weight. In this context, finance is not a back-office function. It is an operational engine that drives whether a company survives, scales, or